[Treatment results for unselected patients with acute myelogenous leukemia. During a 10-year period, August 1984 to July 1994].
In order to analyse the clinical characteristics and outcome in acute myelogenous leukemia, 129 consecutive adult patients admitted to our hospital over a 10-year period, from August 1984 to July 1994, were studied. Their median age was 51 years, 17 (13.2%) of them had antecedent myelodysplastic syndrome (MDS) and 9 (7.0%) had secondary leukemia. Seventy-eight patients (60.5%) were considered eligible for cure-oriented intensive chemotherapy. Forty-four patients were ineligible of one or more of the following; age over 70, antecedent MDS or secondary leukemia. Additional 7 patients were excluded due to concurrent severe diseases. The median survival of the 129 patients was 441 days with an actuarial 5-year survival of 28.6 +/- 4.4%, and the disease-free survival (DFS) decreased with the increasing age of the patient. In 78 patients who were eligible for intensive chemotherapy, complete remission was achieved in 84.6% and overall DFS was 41.1 +/- 5.9% at 5 years, and their survival was longer than that of ineligible patients. It was suggested that considerable selection of patients, for example, due to old age, already existed before visiting our hospital. Analysis of clinical data of unselected patients might enable the development of a rational approach to the management of elderly patients.
Ino
T
T
Department of Internal Medicine, Fujita Health University School of Medicine.
Hirano
M
M
Kojima
H
H
Tsuzuki
M
M
Yamaguchi
T
T
Nomura
T
T
Miyazaki
H
H
Wakita
M
M
Maruyama
F
F
Okamoto
M
M
Matsui
T
T
Ezaki
K
K
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D018572:Disease-Free Survival; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D015122:Mercaptopurine / Q000008:administration & dosage; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D018579:Patient Selection; D011239:Prednisolone / Q000008:administration & dosage; D012074:Remission Induction; D012189:Retrospective Studies; D016896:Treatment Outcome
D003561:Cytarabine; D005047:Etoposide; D011239:Prednisolone; D008942:Mitoxantrone; D015122:Mercaptopurine; D003630:Daunorubicin